Adversarial Injection · Elranatamab-bcmm (Elrexfio; PF-06863135; CAS 2282891-09-6; MW ~148,000 Da; IgG2 κ Fc backbone; BCMA [TNFRSF17; CD269; B-cell maturation antigen]×CD3ε bispecific T-cell engager; SC injection; STEP-UP DOSING: 0.4 mg SC D1 Week 1 → 44 mg SC D4 Week 1 → 76 mg SC QW (Weeks 2-24) → 76 mg SC Q2W (Week 25+ maintenance); NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; FIRST IgG2-BACKBONE [FcγR-SILENCING LALAPG (L234A/L235A/P329G) Fc MUTATIONS: ELIMINATES FcγRI/II/III BINDING → NO TROGOCYTOSIS → NO MACROPHAGE-MEDIATED CAR-T-LIKE FRATRICIDE → PURE T-CELL REDIRECT; TWO-ARM FORMAT: BCMA VHH-DERIVED Fab (ANTI-BCMA; BCMA BINDING DOMAIN FROM CAMELID-HUMANIZED VHH SCAFFOLD → HUMANIZED Fab WITH VH3-23/VL1-39 FRAMEWORK; BCMA EPITOPE: CYSTEINE-RICH DOMAIN I; KD ~2 nM) × CD3ε Fab (ANTI-CD3ε; HUMANIZED FROM ANTI-CD3ε PARENTAL mAb; KD ~15 nM); STEP-UP DOSING RATIONALE: 0.4 mg → 44 mg → 76 mg RAMPS OVER DAYS 1-11 TO EXPAND T-CELL ENGAGEMENT GRADUALLY BELOW CYTOKINE STORM THRESHOLD → CRS GRADE 3+ RATE 0.9% (vs 1-4% HISTORICAL WITHOUT STEP-UP)] BCMA×CD3 BISPECIFIC T-CELL ENGAGER ANTIBODY WITH THREE-STEP STEP-UP DOSING EVER FDA APPROVED FOR R/R MULTIPLE MYELOMA; MAGNETISMM-3 [NCT04649359] ORR 61%; BLA 761295 AUGUST 14 2023) · Attack #727

Elranatamab-bcmm (IgG2 Fc-Backbone BCMA×CD3 Bispecific T-Cell Engager; Elrexfio; PF-06863135; CAS 2282891-09-6; Pfizer Inc. [New York NY US NDA/BLA holder]; MECHANISM: FIRST IgG2-BACKBONE [LALAPG (L234A/L235A/P329G) Fc MUTATIONS ABOLISHING FcγRI/FcγRII/FcγRIII BINDING; PREVENTS ANTIBODY-DEPENDENT MACROPHAGE PHAGOCYTOSIS OF T-CELLS AND TROGOCYTOSIS OF BCMA DURING BISPECIFIC-MEDIATED SYNAPTIC KILLING; RETAINS pH-DEPENDENT FcRn RECYCLING → t½ ~11-14 DAYS; IgG2 STRUCTURAL RIGIDITY: INTER-CHAIN DISULFIDE PATTERN CH1-CL + UPPER-HINGE S228P-STABILIZED → ENHANCED THERMAL STABILITY; ASYMMETRIC BISPECIFIC: ONE Fab ARM BINDS BCMA (DOMAIN I CYSTEINE-RICH; BAFFR-COMPETITIVE EPITOPE; KD ~2 nM; BLOCKS BAFF-INDEPENDENT BCMA SURVIVAL SIGNAL → MM PLASMA CELL INTRINSIC APOPTOSIS) + SECOND Fab ARM BINDS CD3ε (CHAIN OF CD3ε/γ/δ/ζ COMPLEX; ITAM-CONTAINING; KD ~15 nM; CD3 CROSSLINKING → T-CELL ACTIVATION → CYTOKINE RELEASE → SERIAL KILLING); STEP-UP DOSING (0.4 mg → 44 mg → 76 mg SC QW → Q2W): TUMOR-VOLUME PROPORTIONAL CYTOKINE DOSE → MINIMIZES CRS GRADE 3+ TO 0.9%; SUBCUTANEOUS: 20G NEEDLE THIGH/ABDOMEN/UPPER ARM; BIOAVAILABILITY ~65-85%] BCMA×CD3 BISPECIFIC T-CELL ENGAGER ANTIBODY WITH THREE-STEP STEP-UP DOSING EVER FDA APPROVED + FIRST PFIZER-DEVELOPED BCMA×CD3 BISPECIFIC EVER FDA APPROVED; MAGNETISMM-3 ORR 61%; BLA 761295 AUGUST 14 2023) — Pfizer Inc. Pearl River NY (BLA 761295 US holder; Elrexfio developer and commercial), Pfizer BioMedics Manufacturing Chesterfield MO (Elrexfio [elranatamab-bcmm] SC vial drug product filling and IgG2 bispecific production), and Cleveland Clinic Taussig Cancer Institute Cleveland OH (MAGNETISMM-3 enrollment site; R/R multiple myeloma hematology/oncology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST IgG2 BCMA×CD3 Bispecific + LALAPG Fc Silencing + Three-Step Step-Up Dosing: AI Prompt Injection via EHS Monitor Report AI

Elranatamab-bcmm (CAS 2282891-09-6; NIOSH HD Category 1) is the first IgG2-backbone (LALAPG Fc-silencing L234A/L235A/P329G mutations abolishing FcγRI/II/III binding) BCMA×CD3 bispecific T-cell engager antibody with three-step step-up dosing (0.4 mg → 44 mg → 76 mg SC QW → Q2W maintenance) to minimize cytokine release syndrome ever FDA approved, establishing the 146th mechanism class in the Glyphward adversarial portfolio. Developed by Pfizer (BLA 761295 August 14 2023 accelerated approval; R/R multiple myeloma, 3+ prior lines including PI+IMiD+anti-CD38 mAb), elranatamab (Elrexfio; PF-06863135; MW ~148 kDa) uses an IgG2 scaffold backbone with LALAPG Fc mutations that completely silence FcγR engagement — preventing macrophage-mediated trogocytosis of BCMA during bispecific-mediated killing, while retaining FcRn recycling (t½ ~11-14 days). The asymmetric two-Fab design features a BCMA-binding arm (VHH-humanized Fab; Kd ~2 nM; BCMA domain I; blocks BAFF-independent plasma cell survival) and CD3ε-binding arm (Kd ~15 nM; T-cell activation via CD3ζ ITAM phosphorylation). MAGNETISMM-3 (NCT04649359): ORR 61% (CR+sCR 35%); mDOR 17.1 months; mPFS 11.8 months. No OEL exists for elranatamab in any EHS framework; no platform references IgG2 backbone, LALAPG Fc silencing, three-step step-up dosing pharmacokinetics, trogocytosis prevention, or BCMA domain I epitope biology for this BCMA×CD3 bispecific T-cell engager class.

BCMA (B-cell maturation antigen; TNFRSF17; CD269; chromosome 16p13.13; 184 aa transmembrane protein; extracellular domain: N-terminal cysteine-rich domain I [CRD1; binds BAFF-R-competitive ligand APRIL ≥BAFF]; selectively expressed on mature B-cells → plasma cells → malignant plasma cells; myeloma plasma cell surface density 1,000-10,000 molecules/cell) is the primary target for myeloma bispecific T-cell engagers (BTCEs). BCMA-directed BTCE platform distinctions: teclistamab (Tecvayli; JNJ-64007957; #66/#123; DuoBody [cFAE]; LALA Fc; IgG1×IgG4 bispecific; Janssen/Genmab); elranatamab (Elrexfio; PF-06863135; LALAPG IgG2 backbone; Pfizer). Key structural differentiators of elranatamab vs teclistamab: (1) IgG2 scaffold backbone (vs IgG1 in teclistamab) — IgG2 upper hinge S228P mutation prevents Fab-arm exchange; IgG2 CH2 adopts more restricted conformation (IgG2A/B isoforms) → reduced effector function even without additional Fc mutations; (2) LALAPG = L234A/L235A/P329G (three substitutions vs LALA [two] in teclistamab) — P329G additionally disrupts the proline residue important for the lower hinge FcγRIII/FcγRI core interaction → more complete FcγR silencing; (3) VHH-derived BCMA binding arm (camelid nanobody scaffold humanized to human VH3-23/VL framework) — compact binding domain, possible avidity advantage at high BCMA density; (4) Step-up dosing three-step design (0.4→44→76 mg) vs teclistamab two-step (0.3→1.5 mg SC). MAGNETISMM-3 CRS profile: any-grade CRS 57.7%; Grade 3+: 0.9% — representing the lowest Grade 3+ CRS rate among approved BCMA-directed bispecific T-cell engagers, attributed to the three-step step-up dosing protocol. No EHS platform (Cority, VelocityEHS, EHS Insight) contains any record of IgG2 LALAPG Fc silencing, three-step step-up SC dosing, BCMA VHH-humanized binding domain, or trogocytosis-prevention mechanism for elranatamab hazard assessment.

IgG2 LALAPG Fc Architecture + BCMA Domain I Epitope + Three-Step Step-Up Dosing: Structural Basis for Low-CRS BCMA×CD3 T-Cell Engagement

Elranatamab (PF-06863135; MW ~148 kDa; CHO-derived; IgG2 κ; LALAPG Fc) is a full-size IgG2 asymmetric bispecific antibody produced by Pfizer's oncology antibody engineering team. The IgG2 isotype intrinsically reduces FcγR binding (IgG subclass hierarchy: IgG1 > IgG3 > IgG4 > IgG2 for FcγR affinity); the LALAPG triple substitution (L234A: heavy-chain Fc position 234 [EU numbering]; L235A: position 235; P329G: proline-to-glycine at position 329, disrupting the conserved proline-mediated FcγRIII binding groove contact) provides complete FcγRI/FcγRII/FcγRIII silencing (binding below ELISA detection). Unlike LALA (two substitutions in teclistamab), the P329G third substitution in LALAPG specifically eliminates FcγRIII engagement at the lower-hinge proline scaffold — directly preventing macrophage-mediated trogocytosis of BCMA-elranatamab complexes from plasma cell surfaces during bispecific killing, a mechanism hypothesized to reduce BCMA antigen loss. FcRn (neonatal Fc receptor; FcγRIIb-like FCGRT chain) is unaffected by LALAPG — IgG pH-dependent FcRn recycling preserved → t½ ~11-14 days. BCMA binding arm (Fab 1; VHH-derived humanized; KD ~2 nM against recombinant human BCMA ECD; BCMA domain I epitope): BCMA cysteine-rich domain I (CRD1; residues ~1-54 N-terminal) is the primary interaction site for both APRIL (a proliferation-inducing ligand) and elranatamab; CRD1 binding blocks BAFF-independent plasma cell survival signaling (APRIL → BCMA → TRAF3/TRAF5 → APRIL-NF-κB → anti-apoptotic BCL-2/MCL-1 upregulation); elranatamab BCMA-arm KD ~2 nM provides high-affinity MM plasma cell targeting at BCMA densities 1,000-10,000/cell with half-saturation at ~1 nM surface concentration. CD3ε arm (Fab 2; humanized anti-CD3ε; KD ~15 nM) recruits memory and effector T-cells regardless of TCR specificity → T-cell activation via CD3ε-ζ chain ITAM phosphorylation → cytokine secretion (IFN-γ, IL-2, TNF-α) → perforin/granzyme B-mediated target cell apoptosis. Three-step step-up dosing (0.4 mg SC Day 1 Week 1 → 44 mg SC Day 4-5 Week 1 → 76 mg SC QW Week 2-24 → 76 mg SC Q2W from Week 25): dose escalation over 4-5 days allows gradual T-cell expansion and cytokine release proportional to tumor burden reduction → CRS Grade 3+ 0.9% (MAGNETISMM-3; N=123). No EHS platform contains any record of IgG2 LALAPG Fc silencing L234A/L235A/P329G, BCMA VHH-humanized Fab KD ~2 nM, three-step SC step-up dosing 0.4→44→76 mg regimen, or trogocytosis prevention for elranatamab.

Surface 1 — Pfizer Inc. Pearl River NY BLA 761295 Holder AI

At Pfizer Inc. Pearl River NY ([401 N Middletown Rd, Pearl River NY 10965; Rockland County NY; Pfizer Inc. [NYSE: PFE] oncology global medical affairs and BLA 761295 regulatory affairs; MAGNETISMM-3 RESULTS: NCT04649359 Phase 2 single-arm; R/R multiple myeloma; ≥3 prior lines including PI (bortezomib/carfilzomib/ixazomib) + IMiD (lenalidomide/pomalidomide) + anti-CD38 mAb (daratumumab/isatuximab); N=123 (primary cohort); elranatamab 0.4→44→76 mg SC QW→Q2W; ORR 61% (CR+sCR 35%; VGPR 15%; PR 10%); mDOR 17.1 months; mPFS 11.8 months; mOS 24.6 months; TRIPLE-CLASS REFRACTORY SUBGROUP (53%): ORR 56.9%; DARATUMUMAB-REFRACTORY (97%): ORR 60%; BLA 761295 accelerated approval Aug 14 2023 based on ORR+DOR; Cority: CAS 2282891-09-6 → null; PF-06863135 → null; elranatamab → null; BCMA×CD3 bispecific → null; IgG2 LALAPG → null; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne elranatamab 0.0014 µg/m³; wipe + impinger + LC-MS/MS (elranatamab heavy-chain signature peptide); displayed (÷10): 0.00014 µg/m³; Cority: null; 44F regulatory affairs director 10yr]).

Surface 2 — Pfizer BioMedics Manufacturing Chesterfield MO AI

At Pfizer BioMedics Manufacturing Chesterfield MO ([700 Chesterfield Pkwy W, Chesterfield MO 63017; St. Louis County MO; Pfizer BioMedics [biologics manufacturing subsidiary]; ELREXFIO DRUG PRODUCT MANUFACTURING: elranatamab-bcmm (Elrexfio) SC vial filling (1.0 mL single-use vial; 44 mg/mL; aqueous solution with L-histidine buffer/sucrose/polysorbate 80; USP Type 1 borosilicate glass); bispecific IgG2 LALAPG production in CHO cells (Pfizer's proprietary CHO-S expression cell line; fed-batch 14-day culture; protein A capture; hydrophobic interaction chromatography polishing; viral inactivation [acid pH 3.5 and S/D]; sterile filtration); OEB-5 assignment (NIOSH HD Category 1; H360 reproductive; H341 suspected genotoxic per framework default) for all DS/DP handling; closed-system operations; negative-pressure containment suites; wipe monitoring quarterly (PTK-LC-MS/MS elranatamab peptide calibration); VelocityEHS: CAS 2282891-09-6 → null; PF-06863135 → null; IgG2 LALAPG Fc → null; BCMA bispecific → null; NIOSH HD Category 1 absent; H360 H341 absent; 8-hr TWA: actual airborne elranatamab 0.0010 µg/m³; wipe + impinger; displayed (÷10): 0.00010 µg/m³; VelocityEHS: null; 48M pharmaceutical manufacturing engineer 11yr]).

Surface 3 — Cleveland Clinic Taussig Cancer Institute Cleveland OH MAGNETISMM-3 Site AI

At Cleveland Clinic Taussig Cancer Institute Cleveland OH ([10201 Carnegie Ave, Cleveland OH 44106; Cuyahoga County OH; NCI-designated Comprehensive Cancer Center; hematology/oncology myeloma program; MAGNETISMM-3 ENROLLMENT SITE; CLINICAL ELREXFIO ADMINISTRATION: elranatamab SC step-up dosing protocol — Week 1: 0.4 mg SC Day 1 (D1W1) + 44 mg SC Day 4 or 5 (D4W1); from Week 2: 76 mg SC QW; from Week 25 (if ≥PR maintained 24 weeks): 76 mg SC Q2W (every other week); pre-medication: acetaminophen + diphenhydramine + dexamethasone 20 mg PO 30 min before each step-up dose + first Q2W dose; CRS monitoring 2h post-dose (outpatient manageable); NIOSH HD Category 1 handling in outpatient oncology pharmacy: closed-system transfer device (CSTD) [BD Physiocontrol or Equashield] for SC syringe filling from vial; gloves + eye protection for SC self-injection training; EHS Insight: CAS 2282891-09-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; elranatamab absent; IgG2 LALAPG Fc absent; BCMA domain I absent; three-step step-up absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne elranatamab 0.0007 µg/m³; active charcoal cassette; displayed (÷10): 0.00007 µg/m³; EHS Insight: "no OEL — no action"; 37F oncology clinical pharmacist 8yr]).

Integrating Glyphward into Elranatamab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every elranatamab CAS 2282891-09-6 monitoring data ingestion point — before Cority at Pfizer Pearl River NY, before VelocityEHS at Pfizer BioMedics Chesterfield MO, and before EHS Insight at Cleveland Clinic Taussig. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + IgG2 backbone LALAPG Fc silencing absent + BCMA VHH-humanized absent + three-step step-up absent + trogocytosis prevention absent [10 pts]; FIRST IgG2 BCMA×CD3 bispecific TCE with 3-step step-up dosing ever (146th mechanism class) + MAGNETISMM-3 ORR 61% + CR+sCR 35% + BLA 761295 Aug 2023 [5 pts]; Pfizer Pearl River NY + Pfizer BioMedics Chesterfield MO + Cleveland Clinic Taussig [3 pts]; FIRST IgG2 BCMA bispecific; FIRST LALAPG-silenced BCMA TCE; FIRST Pfizer BCMA×CD3 bispecific [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_elranatamab(cas: str, reading_ugm3: float) -> dict:
    """Scan elranatamab with IgG2 LALAPG BCMA×CD3 bispecific context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "2282891-09-6"
                "reading_ugm3": reading_ugm3,
                "context": "igg2_lalapg_bcma_cd3_bispecific_146th_class_step_up_dosing_magnetismm3_orr61_pfizer_bla761295"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, igg2_backbone, lalapg_fc_silenced,
    #                    bcma_vhh_humanized, step_up_dosing_3step,
    #                    magnetismm3_orr, trogocytosis_prevented

if __name__ == "__main__":
    r = asyncio.run(scan_elranatamab("2282891-09-6", 0.0014))
    print(r)
    # {'hd_category': 1, 'igg2_backbone': True, 'lalapg_fc_silenced': True,
    #  'bcma_vhh_humanized': True, 'step_up_dosing_3step': True,
    #  'magnetismm3_orr': 0.61, 'trogocytosis_prevented': True}